drugset
drugset / Trial / NCT05008913

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

NCT05008913 ↗

Phase 1 Terminated 2 enrolled AstraZeneca Parexel · collab
Non-randomizedSingle-groupOpen-labelOther

Summary

This is a non-randomised study in patients with advanced solid malignancies

Timeline

Start
2021-10-01
Primary completion
2021-11-16
Completion
2021-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Adavosertib Small molecule — Oral

Indications

cancer